Recent Advances in the Pharmacotherapy of Chronic Anal Fissure: An Update  by Medhi, Bikash et al.
154 ASIAN JOURNAL OF SURGERY VOL 31 • NO 3 • JULY 2008
© 2008 Elsevier. All rights reserved.
Review Article
Recent Advances in the Pharmacotherapy of 
Chronic Anal Fissure: An Update
Bikash Medhi, Ramya Sankarnarayan Rao, Ajay Prakash, Om Prakash, Lileswar Kaman1 and
Promila Pandhi, Departments of Pharmacology and 1General Surgery, Postgraduate Institute of 
Medical Education and Research, Chandigarh, India.
Surgical sphincterotomy reduces anal tone and sphincter spasm and promotes ulcer healing. Because the
surgery is associated with the side effect of faecal incontinence, pharmacological agents to treat chronic
anal fissure have been explored recently. Glyceryl trinitrate (GTN) ointment (0.2%) has an efficacy of up
to 68% in healing chronic anal fissure, but it is associated with headache as the major and most common
side effect. Though botulinum toxin injected into the anal sphincter healed over 80% of chronic anal fis-
sures, it is more invasive and expensive than GTN therapy. Diltiazem ointment achieved healing of
chronic anal fissure comparable to 0.2% GTN ointment but was associated with fewer side effects. Other
drugs that have been tried are lidocaine, the alpha-adrenergic antagonist indoramin, and the potassium
channel opener minoxidil. [Asian J Surg 2008;31(3):154–63]
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Introduction
Anal fissure is a tear in the anal mucosa extending from
the anal verge toward the dentate line. It was first described
by Recamier in 1829. It is common in people of all ages
and especially in teenagers and young adults. Some stud-
ies suggest that as many as one in five people develop anal
fissure during their lifetime. Anal fissure occurs predomi-
nantly in the midline and most commonly posterior (90%)
with 10% anterior. After childbirth, women tend to have an
anterior fissure, and less than 1% of patients have fissure
both in the anterior and posterior positions.1
Typically, symptoms are severe pain during and after
defaecation and bright red rectal bleeding. Pain is described
as tearing. It may last for minutes or up to an hour. As the
fissure becomes chronic, the bleeding may stop, although
the pain will persist. A minority complain of pruritis,
swelling, prolapse and discharge.2 Most anal fissures are
acute and resolve spontaneously or with conservative
medical management in 10–14 days. It takes 6–8 weeks
for the actual tear to heal. The fissure is said to be chronic
if it is present for longer than 6 weeks. Fissures that fail to
heal become chronic. They usually need further treatment
or intervention to heal. When fissures become large, deep
and chronic, they are called anal ulcers.3 When a fissure is
located in atypical locations or are multiple and fail to
heal following treatment, other conditions such as inflam-
matory bowel disease, neoplasms, leukaemia, syphilis,
tuberculosis, and HIV have to be ruled out.4–6
Previously, anal fissure was thought to be due to severe
constipation or straining at defaecation. However, current
evidence suggests that anal fissure is due to high sphinc-
ter pressure and secondary local ischaemia.7 The poste-
rior commissure is not as well-perfused as other regions
of the anal canal. Here, the inferior rectal artery has a per-
pendicular course through the septa of the internal anal
sphincter.8 Hence, increased intramuscular pressure com-
promises the blood flow, which is further aggravated by
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increased intraluminal pressure. This endodermal ischae-
mia prevents small mechanical tears from healing in a
timely fashion. Anal fissure is usually associated with con-
stipation, laxative abuse, periods of diarrhoea, or some-
times has no obvious reason. Less commonly, fissures are
caused by foreign body insertion or anal intercourse. 
In women, one in 10 cases occurs following childbirth.
The diagnosis is made by the typical history of pain
with defaecation associated with prior constipation.
Chronic anal fissure is accompanied by an external skin
tag and hypertrophied anal papilla. Ulcers can be inspected
by gently parting the posterior anus. Digital and procto-
scopic examination is to be avoided as it triggers severe
pain and spasm of the underlying muscle. Histologically,
one can see acute and chronic infection and granulation
tissue. The sentinel tag is a fibroepithelial polyp covered
by squamous mucosa.8
Treatment
Initially, the patient is managed conservatively. The aim
of treatment is to eliminate constipation, soften the stool
and reduce anal sphincter spasm. Bulk is added to the diet
and stool softener is prescribed. Increased fibre in the diet
softens and bulks the stool. The recommended daily
intake of fibre is 20–25 g. Fibres are naturally found in
fruit and vegetables. They can also be supplemented via
commercially available preparations like psyllium seed,
methylcellulose and calcium polycarbophil. Bulk-forming
laxatives can be used safely. Side effects include flatulence
and bloating. Analgesics relieve pain and a sitz bath relieves
symptoms. A sitz bath is given by immersing the rectal
area in warm water for 10–15 minutes, 2–3 times daily. 
It improves blood flow and relaxes the internal anal sphinc-
ter. The patient is encouraged to drink water and avoid tea
or coffee. A local anaesthetic can be prescribed to relieve
pain and infection. Steroids decrease swelling and inflam-
mation. This medical treatment is effective in patients with
acute anal fissure. Chronic anal fissure requires surgical
or pharmacological intervention.
Surgery
Digital anal dilatation is performed by controlled stretching
around the anal circumference. It is done under general
anaesthesia. By total neuromuscular blockade, the external
anal sphincter is relaxed to avoid unintended contraction
and damage.9 Depending on the toughness of the inter-
nal sphincter force, the magnitude of stretch has to be tai-
lored to the patient’s requirement, but it is associated
with sphincter damage and faecal incontinence.10,11 The
gold standard surgical procedure is internal sphinctero-
tomy. Variations in the technique such as open or close,
midline or lateral, single or multiple have been described.
They provide immediate relief of pain, are simple to per-
form and are widely accepted by patients. However, the
technique is associated with asymmetry of the anal canal,
and irreversible anal sphincter damage and incontinence
may be less frequent after closed sphincterotomy, while
the complication rate and recurrence rate may be lower
after open sphincterotomy.12,13 In a small subgroup of
patients with anal fissure and low maximal anal resting
pressure (MARP), a V-Y anoplasty or an island advance-
ment flap can be considered.14,15 Nyam and Pemberton
showed that lateral internal sphincterotomy healed and
relieved symptoms in 96% of cases, while incontinence
occurred frequently.16 Most episodes of incontinence
were minor and transient, but in a small subgroup, the
incontinence seemed permanent.16 Incontinence includes
the inability to control flatus, mild faecal soiling, or loss
of solid stool. Because anal fissure is more common in
young adults, the long-term result of surgery is a concern.
Recently, several pharmacological agents were investi-
gated as an alternative to surgical therapy. The surgical
approach to chronic anal fissure is reserved for patients
who have tried medical treatment for at least 1–3 months,
but have failed. The goal of lateral sphincterotomy is to
relax the internal sphincter by cutting a small nick in the
internal anal sphincter, which facilitates ulcer healing.
Pharmacotherapy
Drugs tried in the treatment of anal fissure include glyceryl
trinitrate (GTN), isosorbide dinitrate, botulinum toxin,
calcium channel antagonists (CCB) such as nifedipine
and diltiazem, lidocaine, the cholinomimetic bethanecol,
the alpha-adrenergic antagonist indoramin, and the potas-
sium channel opener minoxidil. The different pharmaco-
logical agents that are used in the treatment of chronic
anal fissure are summarized in the Table.17–74
GTN
Contraction of the internal anal smooth muscle depends
on cytoplasmic calcium. Organic nitrates are prodrugs
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that release nitric oxide (NO). NO activates the soluble
form of guanyl cyclase and increases intracellular cyclic
GMP. It promotes dephosphorylation of the myosin light
chain and the reduction of cytosolic calcium leading to
relaxation of smooth muscle in a broad range of tissues.75
Hence, GTN facilitates ulcer healing by dilating blood
vessels, increasing blood flow to injured tissues and reduc-
ing the pressure in the internal anal sphincter. Loder et al
showed a significant decrease in resting anal pressure
using GTN ointment in 1994.76 Lund and Scholefield
used 0.2% GTN ointment and showed that it decreased
MARP by 33% and induced an increase in anodermal
blood flow.19 Studies have shown a healing rate of 33–68%.
Higher doses of NO donor ointment induced faster 
initial healing of chronic anal fissures but did not result
in a superior healing rate in the long term. Compliance 
was decreased due to severe headaches and orthostatic
hypotension.20,24 Other adverse effects include syncopal
attack and tachyphylaxis that limit the use of topical
GTN ointment.26,28,77 The effect of GTN is temporary and
the relapse rate is as high as 35%. GTN should not be used
within 24 hours of erectile dysfunction medications such as
sildenafil, tadalafil and vardenafil. GTN ointment (0.2%)
is applied around the anal opening 2–3 times daily, as well
as before and after bowel movement. Because GTN requires
frequent application, a GTN patch was investigated by
Zuberi et al to improve compliance and acceptability, and
was found to be a suitable alternative.25
Botulinum toxin
The anaerobic bacterium Clostridium botulinum produces
a family of toxins targeted to presynaptic proteins. Acetyl-
choline is stored in vesicles along with other cotransmitters
such as adenosine triphosphate and vasoactive intestinal
polypeptide at neuroeffector junctions. Release of acetyl-
choline occurs on depolarization of the varicosity, which
allows the entry of calcium through voltage dependent
calcium channels. Elevated calcium promotes fusion of
the vesicular membrane with the cell membrane and exo-
cytosis of the transmitter occurs. Botulinum toxin digests
selected proteins in the plasma membrane (syntaxin and
SNAP 25) and the synaptic vesicle (synaptobrevin), and
blocks release of acetylcholine.78 Botulinum toxin A pro-
duces flaccid paralysis of skeletal muscle and diminished
activity of parasympathetic and sympathetic cholinergic
synapses. Studies of injection of botulinum toxin reported
a significant decrease in anal resting pressure of 18–30%.21,79
The therapeutic effect starts within a few hours and lasts
from several weeks to 3–4 months.
When injected into the external anal sphincter, resolu-
tion of pain and ulcer healing occurred in 80% of cases.49
It enabled treatment of chronic uncomplicated anal fis-
sure with increased sphincter tone. It could be admin-
istered on an outpatient basis and did not cause any
lesion or incontinence.80 Higher doses were effective 
in producing long-term healing without complications.50
A minority of patients had temporary incontinence.
Other studies injected botulinum toxin into the internal
anal sphincter. The intrasphincteric injection of toxin was
a safe and effective new option with a healing rate related
to the dose and to the number of puncture sites.51 When
injected into either side of the anterior midline, healing
was improved.52 When combined with GTN at 6 weeks,
healing rates were superior, but no significant difference
was seen at 12 weeks.53
CCBs
CCBs are effective in causing smooth muscle relaxation.
Nifedipine was evaluated for treatment of anal fissure.
With 0.2% nifedipine ointment, a mean reduction of 30%
in MARP was observed.81 Total remission of 95% was
observed at 3 weeks and was 60% after 8 weeks. It was well
tolerated except for flushing and mild headache. There
was no episode of postural hypotension or incontinence.
A calcium-dependent mechanism is required to main-
tain internal sphincter muscle tone. CCB causes relaxation
of gastrointestinal smooth muscle.81,82 Oral diltiazem has
been shown to reduce the resting anal pressure.83 Carapeti
et al explored the possible use of CCB and a cholino-
mimetic to lower anal sphincter pressure.61 Both oral dil-
tiazem and a topical gel containing varying concentrations
of bethanechol were tested on healthy adult volunteers to
determine the dose response characteristics of these agents.
They found that a single dose of 60 mg of diltiazem low-
ered MARP by a mean of 21%. Once-daily diltiazem pro-
duced a clinically insignificant effect, but a twice-daily
regimen reduced anal pressure by a mean of 17%. Diltiazem
gel (2%) produced a maximal 28% reduction, the effect
lasting 3–5 hours. This presented a potential alternative
with low side effects to topical nitrates for the treatment
of anal fissure.61
Carapeti et al conducted their study on patients with
chronic anal fissure.62 Patients were treated with 2% dil-
tiazem gel 3 times daily for 8 weeks. The fissure healed 
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in 67% of patients. There was no significant difference 
in maximum resting sphincter pressure between respon-
ders and nonresponders. There was a significant decrease
in pain score after treatment with diltiazem (p = 0.002).
MARP was significantly lowered (p = 0.0001). No head-
ache or other side effects were reported.62 Jonas et al
assessed the efficacy of oral and topical diltiazem in heal-
ing chronic anal fissure.63 MARP fell by 15% and 23% 
in the oral and topical application groups, respectively.
Fissure healing was 38% in the oral group and 65% in the
topical group after 8 weeks. Oral diltiazem caused side
effects such as rash, headache, nausea, vomiting, decreased
smell and taste, while topically treated groups showed no
side effects.
Knight et al studied the effects of 2% topical diltiazem
in 71 patients.64 Three-quarters experienced healing in
2–3 months and, in a further 2 months, 88% experienced
healing. Minor side effects were perianal dermatitis, one
patient had headache, and six of seven patients with
recurrent fissure were treated successfully by repeat chem-
ical sphincterotomy. Jonas et al did a study to determine
the efficacy of diltiazem in anal fissures that failed to heal
with GTN.65 Thirty-nine patients with chronic anal fis-
sure received GTN therapy, of which 27 patients com-
pleted the course and 12 patients discontinued it. Of the
27 patients who completed the GTN course, 44% were
healed with topical diltiazem, and in 56% of the patients,
the fissure persisted and surgical sphincterotomy was
undertaken. Of the 12 patients who discontinued GTN
therapy, 58% were healed with topical diltiazem.
Dasgupta et al also evaluated the treatment of patients
with anal fissure with diltiazem gel.66 They found that the
fissure healed in 48%, including 75% of the patients who
previously failed to heal with GTN. There were no recur-
rences and no adverse effects. Griffin et al also studied the
role of topical diltiazem in the treatment of chronic anal
fissure in patients who did not respond to GTN therapy.67
They concluded that topical 2% diltiazem is an effective
and safe treatment for patients who have failed to heal
with topical 0.2% GTN. Sphincterotomy could be avoided
in 70% of cases.
Kocher et al performed a randomized controlled trial
assessing the side effects of GTN and diltiazem in the treat-
ment of chronic anal fissure.32 More headache occurred
with GTN than with diltiazem (p = 0.01). There was no
significant difference in healing and symptomatic im-
provement rates between the two groups. Bielecki and
Kolodziejczak conducted a prospective randomized trial
of diltiazem and GTN in the treatment of chronic anal
fissure and concluded that diltiazem and GTN were
equally effective in healing anal fissure.68 However, the
diltiazem trial reported fewer side effects compared to
GTN topical therapy.
Lidocaine and minoxidil
Several studies suggest the topical use of lidocaine in
chronic anal fissure. Muthukumarassamy et al, in a ran-
domized, double-blind trial of 90 patients, reported that
the healing rate with a combination of minoxidil (0.5%)
and lidocaine (5%) was greater compared to control groups
(p = 0.001), and the healing rates of minoxidil and lido-
caine were not significantly different.70 A study conducted
by Maan et al reported that topical use of GTN was signif-
icantly better in reducing MARP and in relieving pain of
patients with chronic anal fissure.37 The result of this ran-
domized, double-blind trial showed a better healing rate
with GTN (93.75%), lidocaine (68.75%) and proctosedyl
(75%) in comparison with the control group given Vaseline
(25%). Perrotti et al, in a randomized, double-blind trial
of 110 patients, showed that nifedipine (0.3%) had a far
better healing rate of 94.5% than the 16.4% in lidocaine-
treated patients (1.5%).71 In the trial done by Bacher et al,
local application of GTN in both acute and chronic anal
fissure had a significantly superior healing rate (80%)
compared to locally applied anaesthetic gel (40%).72
Indoramin
The emerging alpha-adrenergic antagonist indoramin
reduced anal pressure in chronic anal fissure patients.
The work was done by Pitt et al in seven patients who had
a reduction in anal pressure by a mean of > 35%.73 In a
double-blind, randomized, placebo-controlled trial, the
authors found that after 6 weeks of treatment with oral
indoramin (20 mg), healing had occurred in one (7%) patient
in the indoramin group and in two (22%) in the placebo
group (p > 0.1). Additionally, after 3 months, chronic anal
fissure in the indoramin group had recurred and the trial
was terminated early because of poor healing rates.74
A meta-analysis of medical therapy for chronic anal fis-
sure showed that acute fissure and fissure in children may
have a rate of healing that is only marginally better than
placebo, and for chronic fissure, medical therapy is far less
effective than surgery.84
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Conclusion
Although surgical sphincterotomy reduces anal tone and
sphincter spasm and promotes ulcer healing, it is associ-
ated with cases of faecal incontinence. A pharmacological
means to treat chronic anal fissure is an interesting alter-
native. GTN 0.2% ointment has an efficacy of up to 68%
in healing chronic anal fissures, but it is associated with
headache as a major side effect. Botulinum toxin injected
into the anal sphincter healed over 80% of chronic anal
fissures, but it was more invasive and expensive than GTN
therapy. Recently, Mishra et al concluded that both treat-
ments may be considered as first-line treatment even if
less effective than surgery.85 Diltiazem ointment achieved
healing of chronic anal fissure comparable to GTN 0.2%
ointment and was associated with fewer side effects.
Topical treatment is effective for patients with chronic
anal fissure in the short-term and long-term, but for
many patients, it is not a definitive treatment. It can be
offered to those who are ready to take repeated treat-
ments. A longer interval between appearance of symp-
toms and treatment initiation negatively affects fissure
healing and recurrence rate. Floyd et al documented a sig-
nificant change in the medical approach to chronic fis-
sure management.86 The addition of multiple treatment
modalities prolonged time to healing from initial evalua-
tion, but allowed 72% of patients to avoid the need for
permanent sphincter division while maintaining the high-
est rates of healing. Other drugs that have been tried are
lidocaine, the alpha-adrenergic antagonist indoramin,
and the potassium channel opener minoxidil.
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